News

Deal Announcements

Cardioxyl Collects $28 Million New Venture Capital

Thursday, November 8, 2012 5:54:00 AM PDT | VentureDeal
   Chapel Hill, North Carolina  --  Cardioxyl Pharmaceuticals has landed $28 million in new venture capital equity financing, according to an SEC regulatory filing.

Cardioxyl is developing new classes of therapeutic agents for the treatment of cardiovascular disease, initially focusing on acute decompensated heart failure.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Cardioxyl is backed by a syndicate of venture capital firms, including New Enterprise Associates and the Aurora Funds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1